[go: up one dir, main page]

MA27023A1 - Formes cristallines d'azithromycine - Google Patents

Formes cristallines d'azithromycine

Info

Publication number
MA27023A1
MA27023A1 MA27397A MA27397A MA27023A1 MA 27023 A1 MA27023 A1 MA 27023A1 MA 27397 A MA27397 A MA 27397A MA 27397 A MA27397 A MA 27397A MA 27023 A1 MA27023 A1 MA 27023A1
Authority
MA
Morocco
Prior art keywords
azithromycin
crystalline forms
crystalline
forms
Prior art date
Application number
MA27397A
Other languages
English (en)
Inventor
Jane Li Zheng
Vincent Trask Andrew
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27023A1 publication Critical patent/MA27023A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA27397A 2001-05-22 2003-11-14 Formes cristallines d'azithromycine MA27023A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
MA27023A1 true MA27023A1 (fr) 2004-12-20

Family

ID=27404135

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27397A MA27023A1 (fr) 2001-05-22 2003-11-14 Formes cristallines d'azithromycine

Country Status (35)

Country Link
US (10) US6977243B2 (fr)
EP (1) EP1390377B1 (fr)
JP (3) JP2004530703A (fr)
KR (1) KR100574153B1 (fr)
AP (1) AP2003002906A0 (fr)
AR (1) AR036022A1 (fr)
AT (2) ATE319730T1 (fr)
AU (1) AU2002256846B2 (fr)
BG (1) BG108370A (fr)
BR (1) BR0209918A (fr)
CA (1) CA2391659C (fr)
CR (1) CR7159A (fr)
CZ (1) CZ20033154A3 (fr)
DE (2) DE60228345D1 (fr)
DK (1) DK1390377T3 (fr)
EA (2) EA009611B1 (fr)
EE (1) EE200300575A (fr)
ES (2) ES2258142T3 (fr)
GE (1) GEP20084399B (fr)
HU (1) HUP0400446A2 (fr)
IL (1) IL158591A0 (fr)
IS (1) IS7007A (fr)
MA (1) MA27023A1 (fr)
MX (1) MXPA03010028A (fr)
MY (1) MY129319A (fr)
NO (2) NO321894B1 (fr)
NZ (2) NZ539801A (fr)
PA (1) PA8545701A1 (fr)
PE (1) PE20021064A1 (fr)
PL (1) PL367091A1 (fr)
PT (1) PT1390377E (fr)
SK (1) SK14402003A3 (fr)
TN (1) TNSN03121A1 (fr)
WO (1) WO2002094843A1 (fr)
YU (1) YU91603A (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
DK1152765T3 (da) * 1998-11-30 2005-01-31 Teva Pharma Ethanolat af azithromycin, fremgangsmåde til fremstilling og farmaceutiske sammensætninger deraf
WO2002015842A2 (fr) * 2000-08-23 2002-02-28 Wockhardt Limited Procede de preparation d'azithromycine anhydre
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
MXPA03010028A (es) * 2001-05-22 2004-02-12 Pfizer Prod Inc Formas cristalinas de azitromicina.
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
IL161996A0 (en) 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
EP1478347A1 (fr) 2002-02-01 2004-11-24 Pfizer Products Inc. Preparation d'azithromycine en granulat sec
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (fr) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate d'azithromycine et methode de production connexe
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1648473B1 (fr) 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Dose unique a dissolution rapide d'azithromycine
EP1878432A1 (fr) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Azithromycine à dissolution rapide pour dose unique
CA2678124C (fr) * 2003-11-17 2014-10-07 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
EP1776365B1 (fr) * 2004-06-02 2011-08-03 Sandoz Ag Intermediaire de meropenem sous forme cristalline
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
EP1904510A1 (fr) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Procede de formation de particules d'azithromycine amorphe
EP1928826B1 (fr) * 2005-09-21 2013-04-24 4Sc Ag Sels de chlorhydrate de sulfonylpyrrole comme inhibiteurs de l'histone deacetylase
WO2007053427A2 (fr) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Nouveaux procédés de synthèse de dérivés de benzamide de type pipérazinyle et diazapanyle
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
CA2656057C (fr) * 2006-06-16 2012-10-02 H. Lundbeck A/S Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
RU2496780C2 (ru) * 2006-10-27 2013-10-27 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Твердые формы
CA2570949A1 (fr) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Solvate d'ibandronate sodique et de propyleneglycol et methodes de preparation connexes
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
BR112012022910B1 (pt) 2010-03-12 2021-08-10 Omeros Corporation Compostos inibidores de pde10, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos para tratar distúrbios neurológicos em um animal de sangue quente
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
EP2760859A1 (fr) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Formes cristalline d'azilsartan et leur préparation et leurs utilisations
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP3108879A1 (fr) 2015-06-25 2016-12-28 Cassiopea S.p.A. Formulation à concentration élevée
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
CN111278808B (zh) * 2017-09-07 2024-04-26 安兹克斯特殊目的有限责任公司 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI7910768A8 (en) 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (fr) 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE29724846U1 (de) * 1996-07-29 2004-12-16 Abbott Laboratories, Abbott Park Herstellung von kristalliner Form II von Clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (fr) 1998-08-21 2002-01-29 Apotex Inc. Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
DK1152765T3 (da) * 1998-11-30 2005-01-31 Teva Pharma Ethanolat af azithromycin, fremgangsmåde til fremstilling og farmaceutiske sammensætninger deraf
AU5820400A (en) * 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
ATE388159T1 (de) 2000-01-04 2008-03-15 Teva Pharma Verfahren zur herstellung von azithromycin- dihydrat
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (fr) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited Fabrication d'une composition pharmaceutique liquide limpide d'azithromycine
WO2002010144A1 (fr) 2000-07-25 2002-02-07 Laboratorio Silanes, S.A. De C.V. Procede permettant de preparer en une seule etape de la 7,16-dioxa-2-aza-10-o-cladinosyl-12-o-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethylbicyclo[11.2.1]hexa-deca-1(2)-en-8-one et permettant d'obtenir une nouvelle forme de 9-desoxo-9a-aza-9a-methyl-9a-homoerythromycine a
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (fr) 2000-08-01 2002-02-07 Shiva Prasad Singh Élaboration d'azithromycine anhydre
WO2002015842A2 (fr) 2000-08-23 2002-02-28 Wockhardt Limited Procede de preparation d'azithromycine anhydre
EE05200B1 (et) 2000-11-27 2009-08-17 Biochemie S.A. Asitromtsiin monohdraadina, selle valmistamismeetod ja selle kasutamine ravimkoostises
IN190080B (fr) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
MXPA03010028A (es) * 2001-05-22 2004-02-12 Pfizer Prod Inc Formas cristalinas de azitromicina.
EP1446010B1 (fr) 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Compositions d'azithromycine stabilisees

Also Published As

Publication number Publication date
HUP0400446A2 (hu) 2004-09-28
SK14402003A3 (sk) 2004-06-08
AP2003002906A0 (en) 2003-12-31
EA200500630A1 (ru) 2006-02-24
CA2391659C (fr) 2006-05-30
CZ20033154A3 (en) 2004-04-14
PL367091A1 (en) 2005-02-21
WO2002094843A1 (fr) 2002-11-28
US7309782B2 (en) 2007-12-18
AR036022A1 (es) 2004-08-04
PE20021064A1 (es) 2002-11-21
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
IS7007A (is) 2003-10-30
KR20040014525A (ko) 2004-02-14
JP2006152002A (ja) 2006-06-15
CR7159A (es) 2004-02-23
US7081525B2 (en) 2006-07-25
US20050256062A1 (en) 2005-11-17
US20040043944A1 (en) 2004-03-04
NO20035177D0 (no) 2003-11-21
EA009611B1 (ru) 2008-02-28
NO321894B1 (no) 2006-07-17
US6977243B2 (en) 2005-12-20
EA007618B1 (ru) 2006-12-29
DK1390377T3 (da) 2006-06-19
US20030162730A1 (en) 2003-08-28
KR100574153B1 (ko) 2006-04-25
US20050256063A1 (en) 2005-11-17
US20040043945A1 (en) 2004-03-04
JP4584162B2 (ja) 2010-11-17
ATE404575T1 (de) 2008-08-15
ES2258142T3 (es) 2006-08-16
PT1390377E (pt) 2006-06-30
EA200301115A1 (ru) 2004-04-29
BR0209918A (pt) 2004-03-30
MY129319A (en) 2007-03-30
US7053192B2 (en) 2006-05-30
US7307156B2 (en) 2007-12-11
NZ539801A (en) 2006-10-27
NO20061049L (no) 2003-05-12
US20050090459A1 (en) 2005-04-28
US20040138149A1 (en) 2004-07-15
YU91603A (sh) 2006-08-17
CA2391659A1 (fr) 2002-11-22
ATE319730T1 (de) 2006-03-15
EP1390377B1 (fr) 2006-03-08
US7105179B2 (en) 2006-09-12
DE60209704T2 (de) 2006-11-16
DE60228345D1 (de) 2008-09-25
GEP20084399B (en) 2008-06-10
EP1390377A1 (fr) 2004-02-25
DE60209704D1 (de) 2006-05-04
ES2310886T3 (es) 2009-01-16
US7282486B2 (en) 2007-10-16
NZ529118A (en) 2005-10-28
US20050245469A1 (en) 2005-11-03
AU2002256846B2 (en) 2007-04-05
MXPA03010028A (es) 2004-02-12
JP2007161726A (ja) 2007-06-28
BG108370A (bg) 2004-11-30
US20040082527A1 (en) 2004-04-29
TNSN03121A1 (en) 2005-12-23
JP2004530703A (ja) 2004-10-07
IL158591A0 (en) 2004-05-12
EE200300575A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
MA27023A1 (fr) Formes cristallines d'azithromycine
FR20C1039I2 (fr) Derives de l'uk-2a
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
NO20043110L (no) Direkte komprimerbare formuleringer av azitromycin
PT1169314E (pt) Base cristalina de citalopram
EP1442038A4 (fr) Formes cristallines d'antibiotiques a base de carbapeneme et procedes de preparation
DK1451192T3 (da) Ny krystallinsk forbindelse
NO20040198L (no) Dolastatin 10 derivater
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
PT1119430E (pt) Fresa
PT1250321E (pt) Composicao de gliburida
PT1100326E (pt) Microcapsulas de libertacao activada por bases
MA26845A1 (fr) Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-
EP1418949A4 (fr) Inhibiteur de methylation d'adn
FR2824092B1 (fr) Ensemble d'elements de construction
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
MA27240A1 (fr) Derives d'imidazoquinoleine
AR028070A1 (es) Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol
IS5821A (is) Kristalluð form af ósanetant
ITBO20010485A0 (it) Unita' di ventilazione
NO20030419D0 (no) 16<alfa>-metyl- eller etyl-substituerte estrogener
FI20015039L (fi) Tilaajatunnuksen siirrettävyys
EP1453813A4 (fr) PURIFICATION AMELIOREE DE 4, 4 (5 )-DI- i T /i -BUTYLCY CLOHEXANO-18-COURONNE-6
ITMI991721A0 (it) Metodo di cristallizzazione di sorbitolo e sorbitolo cristallizzato co si' ottenuto
ITMI20020052A1 (it) Procedimento per l'idrolisi selettiva di nucleosidi poliesteri